Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Papuć, Ewa | Kurys-Denis, Ewa | Krupski, Witold | Tatara, Marcin | Rejdak, Konrad
Article Type: Research Article
Abstract: Background: Alzheimer’s disease (AD) is known to exhibit well characterized pathologies including the extracellular accumulation of amyloid plaques, intra-axonal presence of neurofibrillary tangles, and glial hypertrophy. Nevertheless, the nature of myelin pathology in AD has not been well studied. Recent studies on animal models of AD, however, revealed focal demyelination within amyloid-β plaques in hippocampus. Objectives: In a view of this finding, we decided to assess humoral response against proteins of myelin sheath in AD, in the hope of identifying early biomarkers of memory loss and neuropathological process characteristic of AD. Methods: We assessed …antibodies levels against proteins of the myelin sheath: myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), myelin-associated glycoprotein (MAG), and proteolipoprotein (PLP) in sera of 26 AD patients and 26 healthy controls, using commercially available ELISA system (Mediagnost, Germany). Results: In the AD patient subgroup, significantly higher titers were observed for all types of assessed IgG autoantibodies compared to healthy control subjects (anti-MOG, anti-MAG, anti-MBP, anti-PLP). The titers of most of the investigated IgM antibodies were also higher in AD patients (p < 0.05), with the exception of anti-MAG IgM antibodies (p > 0.05). Conclusion: The study provides the evidence for the significantly increased production of autoantibodies against proteins of myelin sheath in AD. These results can be of importance in the light of emerging data from animal models of AD, indicating early demyelination of hippocampal region. Further studies on larger population are necessary to confirm whether these autoantibodies could serve as early biomarkers of AD in humans. Show more
Keywords: Alzheimer’s disease, autoantibodies, glial cells, humoral response, immune system, oligodendrocytes
DOI: 10.3233/JAD-150309
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 115-121, 2015
Authors: Kemppainen, Nina | Joutsa, Juho | Johansson, Jarkko | Scheinin, Noora M. | Någren, Kjell | Rokka, Johanna | Parkkola, Riitta | Rinne, Juha O.
Article Type: Research Article
Abstract: The aim of this longitudinal positron emission tomography (PET) study was to evaluate the interrelationship between brain metabolism and amyloid accumulation during the disease process from mild cognitive impairment (MCI) to Alzheimer’s disease (AD). Nine MCI patients, who converted to AD between two and five years, and nine healthy subjects underwent [11 C]PIB and [18 F]FDG PET scans at baseline and at 5 years. [11 C]PIB uptake was clearly higher in MCI patients at baseline compared to controls and spread extensively to the cerebral cortex during the conversion to AD. [18 F]FDG uptake was reduced especially in the temporal-parietal regions …in MCI compared to controls at baseline, and widely over the cortex at the 5-year follow-up. The reduction in metabolism during the follow-up was significant in the posterior brain regions. In addition, brain amyloid load was positively associated with metabolism in posterior brain regions in MCI, but not after conversion to AD. The results suggest that there are interactions between brain amyloid accumulation and metabolism during the AD process, including a possible compensatory upregulation of posterior brain metabolism in the early phase. Show more
Keywords: Alzheimer’s disease, [11C]PIB, [18F]FDG, follow-up, mild cognitive impairment, PET
DOI: 10.3233/JAD-150190
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 123-133, 2015
Authors: Hutchings, Rosalind | Hodges, John R. | Piguet, Olivier | Kumfor, Fiona
Article Type: Research Article
Abstract: Background: Skills such as empathy and emotion recognition rely on a multi-dimensional socio-emotional system. Increasingly, evidence suggests that socio-emotional cognition is affected in frontotemporal dementia and Alzheimer’s disease (AD), to varying degrees. However, the specific dimensions of socio-emotional behavior and their neuroanatomical correlates have been relatively unexplored. Objective: The current study aimed to: (i) determine how different dimensions of socio-emotional cognition are affected in behavioral-variant frontotemporal dementia (bvFTD), semantic dementia (SD), and AD; (ii) investigate insight into socio-emotional cognition; (iii) identify the neural correlates subserving dimensions of socio-emotional cognition. Methods: Sixteen bvFTD, …15 SD, 10 AD patients, and 17 controls were included. Each participant and a nominated ‘informant’ completed the socio-emotional questionnaire; a 30-item rating scale assessing five dimensions of socio-emotional cognition (empathy, emotion recognition, social conformity, antisocial behavior, sociability). Results: SD and bvFTD participants were rated lower on measures of empathy and emotion recognition compared to AD participants and Controls, while other dimensions were relatively intact. In contrast, participants with AD were rated similarly to Controls across all dimensions. SD and bvFTD groups demonstrated reduced insight into socio-emotional dysfunction. Grey matter intensity in the temporal regions correlated with empathy and emotion recognition. Social conformity was associated with the orbitofrontal cortex and amygdala. Conclusion: Distinct profiles in typically presenting bvFTD, SD, and AD illustrate preliminary evidence of the utility of socio-emotional cognition in diagnostic clarification. This is an important starting point in understanding socio-emotional functioning in younger-onset dementia, paving the way for targeted management and interventions. Show more
Keywords: Alzheimer’s disease, carer, cognition, frontotemporal dementia, social behavior, temporal pole
DOI: 10.3233/JAD-150245
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 135-147, 2015
Authors: Hosono, Takashi | Mouri, Akihiro | Nishitsuji, Kazuchika | Jung, Cha-Gyun | Kontani, Masanori | Tokuda, Hisanori | Kawashima, Hiroshi | Shibata, Hiroshi | Suzuki, Toshiharu | Nabehsima, Toshitaka | Michikawa, Makoto
Article Type: Research Article
Abstract: It is believed that the amyloid β -protein (Aβ ) plays a causative role in the development of Alzheimer’s disease (AD). The amyloid-β protein precursor (Aβ PP), a substrate of Aβ , and β -secretase and γ -secretase complex proteins, which process Aβ PP to generate Aβ , are all membrane proteins. Thus, it is reasonable to assume that alterations in brain lipid metabolism modulate Aβ PP and/or Aβ metabolism. However, the role of cellular polyunsaturated fatty acids in Aβ PP processing has not been completely understood yet. We report here that 4 months of treatment of Tg2576 …mice with an arachidonic acid (ARA)- or a docosahexaenoic acid (DHA)-containing (ARA+ or DHA+) diet prevented memory impairment at 13 months of age. Although, Aβ PP processing to generate soluble Aβ PP and induce Aβ synthesis was enhanced, Aβ 1 - 42 /Aβ 1 - 40 ratio decreased in 14-month-old Tg2576 mice fed with the ARA+ or DHA+ diet. The ARA+ or DHA+ diet did not alter the Aβ PP levels and the expression levels of Aβ -degrading enzymes. In cortical primary neuron cultures, ARA or DHA treatment also increased soluble Aβ PP and Aβ 1 - 40 levels, and decreased Aβ 1 - 42 /Aβ 1 - 40 ratio, which are similar to what were observed in Tg2576 mice fed with ARA+ or DHA+ diet. These findings suggest that not only the DHA+ diet, but also the ARA+ diet could prevent cognitive dysfunction in Tg2576 mice through the alteration of Aβ PP processing. Show more
Keywords: Alzheimer’s disease, amyloid β-protein, amyloid β-protein precursor, arachidonic acid, docosahexaenoic acid, memory impairment
DOI: 10.3233/JAD-150341
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 149-162, 2015
Authors: Serna, Adriana | Contador, Israel | Bermejo-Pareja, Félix | Mitchell, Alex J. | Fernández-Calvo, Bernardino | Ramos, Francisco | Villarejo, Alberto | Benito-León, Julián
Article Type: Research Article
Abstract: Early separation of mild cognitive impairment (MCI) from normal aging and mild cases of dementia remains a challenge, especially in the general population. We aimed to analyze the diagnostic accuracy of a brief neuropsychological battery (BNB) in dementia and MCI cases from the Neurological Disorders in Central Spain (NEDICES) population-based cohort study. We screened 3,891 participants into dementia and non-dementia groups using a two-phase procedure: screening (MMSE-37 and Pfeffer-11) and clinical diagnosis by specialists (DSM-IV criteria). We selected subsequently a subsample of dementia (n = 98), MCI (n = 71), and cognitively healthy (n = 123) participants matched in socio-demographic characteristics. The clinical …validity of each test of the BNB was determined by the area under the ROC curve. We determined the best combination of tests to classify individuals into the diagnostic groups by logistic regression analyses. The results indicated that dementia and MCI groups could be best discriminated from the healthy control group on the basis of their scores on the semantic verbal fluency and delayed recall subtests of the BNB. As for discriminating the MCI group from the dementia group, immediate recall tasks (stories and pictures) yielded the highest level of accuracy. Probably the most interesting finding is that the verbal fluency task consistently allowed discrimination among the diagnostic groups. Overall, subtests of the BNB are more accurate in differentiating dementia patients than MCI patients from healthy controls. In this population-based sample, a more fine-grained discrimination that includes MCI patients should follow a systematic subtest-wise analysis and decision. Show more
Keywords: Dementia, memory, mild cognitive impairment, neuropsychological assessment, population based-study, test accuracy
DOI: 10.3233/JAD-150086
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 163-173, 2015
Authors: Li, Qiao-Xin | Villemagne, Victor L. | Doecke, James D. | Rembach, Alan | Sarros, Shannon | Varghese, Shiji | McGlade, Amelia | Laughton, Katrina M. | Pertile, Kelly K. | Fowler, Christopher J. | Rumble, Rebecca L. | Trounson, Brett O. | Taddei, Kevin | Rainey-Smith, Stephanie R. | Laws, Simon M. | Robertson, Joanne S. | Evered, Lisbeth A. | Silbert, Brendan | Ellis, Kathryn A. | Rowe, Christopher C. | Macaulay, S. Lance | Darby, David | Martins, Ralph N. | Ames, David | Masters, Colin L. | Collins, Steven | and for the AIBL Research Group
Article Type: Research Article
Abstract: Background: The cerebrospinal fluid (CSF) amyloid-β (Aβ)1-42 , total-tau (T-tau), and phosphorylated-tau (P-tau181P ) profile has been established as a valuable biomarker for Alzheimer’s disease (AD). Objective: The current study aimed to determine CSF biomarker cut-points using positron emission tomography (PET) Aβ imaging screened subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, as well as correlate CSF analyte cut-points across a range of PET Aβ amyloid ligands. Methods: Aβ pathology was determined by PET imaging, utilizing 11 C-Pittsburgh Compound B, 18 F-flutemetamol, or 18 F-florbetapir, in 157 AIBL …participants who also underwent CSF collection. Using an INNOTEST assay, cut-points were established (Aβ1-42 >544 ng/L, T-tau <407 ng/L, and P-tau181P <78 ng/L) employing a rank based method to define a “positive” CSF in the sub-cohort of amyloid-PET negative healthy participants (n = 97), and compared with the presence of PET demonstrated AD pathology. Results: CSF Aβ1-42 was the strongest individual biomarker, detecting cognitively impaired PET positive mild cognitive impairment (MCI)/AD with 85% sensitivity and 91% specificity. The ratio of P-tau181P or T-tau to Aβ1-42 provided greater accuracy, predicting MCI/AD with Aβ pathology with ≥92% sensitivity and specificity. Cross-validated accuracy, using all three biomarkers or the ratio of P-tau or T-tau to Aβ1-42 to predict MCI/AD, reached ≥92% sensitivity and specificity. Conclusions: CSF Aβ1-42 levels and analyte combination ratios demonstrated very high correlation with PET Aβ imaging. Our study offers additional support for CSF biomarkers in the early and accurate detection of AD pathology, including enrichment of patient cohorts for treatment trials even at the pre-symptomatic stage. Show more
Keywords: Alzheimer’s disease, amyloid-β, cerebrospinal fluid biomarkers, positron emission tomography Aβ imaging, tau
DOI: 10.3233/JAD-150247
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 175-187, 2015
Authors: Schmidt, Christian | Gerlach, Nicole | Schmitz, Matthias | Thom, Tobias | Kramer, Katharina | Friede, Tim | Zerr, Inga
Article Type: Research Article
Abstract: Background/Objective: Apolipoprotein E (ApoE) has an active part in the pathogenesis of Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) and plasma level alterations have been reported in AD patients. In search of a biomarker potentially predictive of cognitive, functional, or motor decline, we analyzed the CSF to serum ratios of ApoE levels (CSF/serum ApoE) in AD patients in this regard. Methods: Subjects with newly diagnosed AD were followed within a longitudinal observational study (rpAD study). Annual neuropsychological testing and physical examination were performed. Multiple regression analyses were used to determine possible associations of the ApoE CSF/serum concentration ratios …and velocity of decline on a variety of cognitive, functional and motor scales (MMSE, iADL, bADL, GDS, UPDRSIII) adjusted for relevant co-variables. Results: CSF/serum ratios of ApoE levels were associated with progression on the UPDRSIII (change of UPDRSIII slope [pt/yr] per unit of ApoE CSF/serum = –0.06, p < 0.01) and instrumental ADL scale (change of iADL slope [pt/yr] per unit of ApoE CSF/serum = 0.01, p = 0.01) (“the lower the ratio, the faster the deterioration” and vice versa). Secondarily, higher age at onset was associated with faster UPDRSIII progression, antidepressant use with faster iADL decline, and better baseline function with more rapid decline on either MMSE, iADL, or GDS scale. Conclusion: Here, CSF/serum ApoE at time of AD diagnosis was shown to be inversely associated with medium-term functional and motor progression. Whether this ratio qualifies for the use as a predictive biomarker must be validated in larger cohort studies over the long term. Show more
Keywords: Alzheimer’s disease, apolipoprotein E, biomarker, cerebrospinal fluid, cognition
DOI: 10.3233/JAD-150286
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 189-196, 2015
Authors: Brueggen, Katharina | Dyrba, Martin | Barkhof, Frederik | Hausner, Lucrezia | Filippi, Massimo | Nestor, Peter J. | Hauenstein, Karlheinz | Klöppel, Stefan | Grothe, Michel J. | Kasper, Elisabeth | Teipel, Stefan J. | and the EDSD study group
Article Type: Research Article
Abstract: Background: Hippocampal grey matter (GM) atrophy predicts conversion from mild cognitive impairment (MCI) to Alzheimer’s disease (AD). Pilot data suggests that mean diffusivity (MD) in the hippocampus, as measured with diffusion tensor imaging (DTI), may be a more accurate predictor of conversion than hippocampus volume. In addition, previous studies suggest that volume of the cholinergic basal forebrain may reach a diagnostic accuracy superior to hippocampal volume in MCI. Objective: The present study investigated whether increased MD and decreased volume of the hippocampus, the basal forebrain and other AD-typical regions predicted time to conversion from MCI …to AD dementia. Methods: 79 MCI patients with DTI and T1 -weighted magnetic resonance imaging (MRI) were retrospectively included from the European DTI Study in Dementia (EDSD) dataset. Of these participants, 35 converted to AD dementia after 6–46 months (mean: 21 months). We used Cox regression to estimate the relative conversion risk predicted by MD values and GM volumes, controlling for age, gender, education and center. Results: Decreased GM volume in all investigated regions predicted an increased risk for conversion. Additionally, increased MD in the right basal forebrain predicted increased conversion risk. Reduced volume of the right hippocampus was the only significant predictor in a stepwise model combining all predictor variables. Conclusion: Volume reduction of the hippocampus, the basal forebrain and other AD-related regions was predictive of increased risk for conversion from MCI to AD. In this study, volume was superior to MD in predicting conversion. Show more
Keywords: Diffusion tensor imaging, magnetic resonance imaging, Mild Cognitive Impairment, Alzheimer’s disease, atrophy, basal forebrain, cholinergic, early diagnosis
DOI: 10.3233/JAD-150063
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 197-204, 2015
Authors: Hanson, Angela J. | Bayer, Jennifer L. | Baker, Laura D. | Cholerton, Brenna | VanFossen, Brian | Trittschuh, Emily | Rissman, Robert A. | Donohue, Michael C. | Moghadam, Setareh H. | Plymate, Stephen R. | Craft, Suzanne
Article Type: Research Article
Abstract: Background: High intake of saturated fat (SF) and glycemic index (GI) foods is a risk factor for sporadic Alzheimer’s disease. Meal challenges may elucidate mechanisms that contribute to this risk, enabling development of targeted interventions. Objective: To assess cognitive and metabolic changes after a meal high in SF and GI calories (HIGH) versus a meal low in these macronutrients (LOW) in older adults with and without cognitive impairment, and with and without the apolipoprotein E4 risk factor. Methods: 46 adults with either cognitive impairment (CI) or normal cognition (NC) ingested a LOW …(25% total fat, 7% SF, GI <55) and a HIGH meal (50% total fat, 25% SF, GI >70) in a blinded random fashion. Participants then underwent cognitive testing and blood sampling for metabolic and Alzheimer’s disease biomarkers. Data were analyzed using repeated measures ANOVA and Spearman correlations. Results: E4–adults with NC demonstrated lower delayed memory scores after the HIGH compared to the LOW meal, whereas normal E4+ and CI E4– groups had higher scores after the HIGH meal (ANOVA p = 0.03). These findings were associated with meal-induced changes in glucose (p = 0.05), insulin (p = 0.004), triglycerides (p < 0.01), and plasma Aβ42 (p = 0.05). Conclusions: These preliminary data suggest that cognitive performance of adults without CI may worsen following high SF and sugar meals, whereas adults with CI or those at risk for CI due to E4 status may benefit acutely from such meals. Furthermore, plasma Aβ was affected by meal type, suggesting a relationship between metabolic response and amyloid regulation. Show more
Keywords: Alzheimer’s disease, APOE genotype, glycemic index, insulin, plasma amyloid, saturated fat, triglycerides
DOI: 10.3233/JAD-150273
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 205-218, 2015
Authors: Alam, John J.
Article Type: Research Article
Abstract: Background: P38 mitogen activated protein kinase (MAPK) α modulates microglia-mediated inflammatory responses and a number of neuronal physiological processes. Objective: To evaluate pre-clinically the pharmacological effects in the brain of p38 MAPKα inhibition with a brain-penetrant specific chemical antagonist. Methods: VX-745, a blood-brain barrier penetrant, highly selective p38 MAPKα inhibitor, and clinical stage investigational drug, was utilized. Initially, a pilot study in 26-month-old Tg2576 mice was conducted. Subsequently, a definitive dose-response study was conducted in aged (20–22 months) rats with identified cognitive deficits; n = 15 per group: vehicle, 0.5, 1.5, and 4.5 mg/kg …VX-745 by oral gavage twice daily for 3 weeks. Assessments in aged rats included IL-1β, PSD-95, TNFα protein levels in hippocampus; and Morris water maze (MWM) test for cognitive performance. Results: Drug effect could not be assessed in Tg2576 mice, as little inflammation was evident. In cognitively-impaired aged rats, VX-745 led to significantly improved performance in the MWM and significant reduction in hippocampal IL-1β protein levels, though the effects were dissociated as the MWM effect was evident at a lower dose level than that required to lower IL-1β. Drug concentration-effect relationships and predicted human doses were determined. Conclusions: Selective inhibition of p38 MAPKα with VX-745 in aged rats reduces hippocampal IL-1β levels and improves performance in the MWM. As the two effects occur at different dose levels, the behavioral effect appears to be via a mechanism that is independent of reducing cytokine production. The predicted human doses should minimize risks of systemic toxicity. Show more
Keywords: Aged rats, Alzheimer’s disease, amyloid plaque, cognition, IL-1β , p38 MAPKα , Tg2576 mouse
DOI: 10.3233/JAD-150277
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 219-227, 2015
Authors: Fereshtehnejad, Seyed-Mohammad | Johannsen, Peter | Waldemar, Gunhild | Eriksdotter, Maria
Article Type: Research Article
Abstract: Background: Two dementia quality registries have been developed in Denmark and Sweden with the aim to assess quality of dementia care based on adherence to national guidelines. Objective: To compare patient characteristics, diagnostics, treatment, and quality indicators of dementia care among patients referred to specialist units in Sweden and Denmark. Methods: Data from the Swedish Dementia Registry (SveDem) and the Danish Dementia Registry were merged. Newly diagnosed dementia cases referred to memory clinics during 2007–2012 were included (19,629 Swedish and 6,576 Danish patients). Results: The median duration between initial …assessment and confirmed diagnosis was 56 and 57 days in Sweden and Denmark, respectively. Brain imaging using MRI was twice as common in Sweden. A diagnosis of dementia was established at an average MMSE of 21. An etiological diagnosis was concluded in 89.6% of the Swedish and 87.3% of the Danish cases. Alzheimer’s disease (AD) was the most common disorder (47.7% in Denmark and 36.6% in Sweden); however, more cases were diagnosed as mixed AD in Sweden (24.7% versus 10.6% ). More than 80% of patients with AD, dementia with Lewy bodies, and Parkinson’s disease with dementia were treated with anti-dementia drugs. Conclusion: The targets of several quality indicators in both registries were met, such that structural brain imaging and MMSE were performed in >90% and an etiological diagnosis was concluded in >80% of the patients. However, there were also results of concern. The diagnosis of dementia was established at a mean MMSE of 21, which is already late in the course of most dementia disorders. A higher chance of vascular findings following the higher rate of MRI in Sweden may have resulted in more mixed AD diagnosis, which could be one explanation for diagnostic differences but also highlights the need to harmonize diagnostic criteria. Show more
Keywords: Alzheimer’s disease, dementia, diagnosis, quality indicators, quality registries, therapy
DOI: 10.3233/JAD-150144
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 229-239, 2015
Authors: Heiskanen, Jari | Hartikainen, Sirpa | Roine, Risto P. | Tolppanen, Anna-Maija
Article Type: Research Article
Abstract: Background and Objectives: Persons with Alzheimer’s disease (AD) have been suggested to receive suboptimal treatment. We studied the 30-day mortality after ischemic stroke, hemorrhagic stroke, or myocardial infarction in individuals with or without AD. Methods: An exposure matched cohort of all Finnish community-dwellers diagnosed with clinically verified AD in 2005–2012 (n = 73,005) and 1–4 matched comparison persons/AD-affected person (n = 215,449). Data on 30-day mortality after ischemic stroke (n = 16,419; deaths: n = 2,748), hemorrhagic stroke (n = 3,570; deaths: n = 1,224), and myocardial infarction (n = 15,304; deaths: n = 3,804) were obtained from the National Hospital Discharge register. The main …analyses were restricted to first-ever events. Results: Persons with AD had slightly higher 30-day mortality after ischemic stroke (adjusted HR 1.36, 95% Confidence interval (CI) 1.24,1.49), hemorrhagic stroke (adjusted HR 1.11, 95% CI 0.98,1.25), or myocardial infarction (adjusted HR, 1.40, 9% CI 1.30,1.51). The associations were not affected by age, gender, or co-morbidities and remained similar when patients with previous ischemic strokes or infarctions were included. The absolute risk increase in 30-day mortality after ischemic or hemorrhagic stroke and myocardial infarction were 4.9% (95% CI 3.3,6.5), 3.3% (95% CI – 1.6,8.2), and 7.5% (95% CI 5.0,10.0), respectively. Conclusions: Although the 30-day mortality was somewhat higher in the AD cohort, the absolute differences were small indicating that acute treatment was not notably inferior in AD patients. The slightly higher mortality was not explained by co-morbidities but may reflect the higher mortality of AD persons in general, or treatment practice of patients with severe cognitive impairment. Show more
Keywords: Alzheimer’s disease, mortality, myocardial infarction, stroke
DOI: 10.3233/JAD-150259
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 241-249, 2015
Authors: Anderkova, Lubomira | Eliasova, Ilona | Marecek, Radek | Janousova, Eva | Rektorova, Irena
Article Type: Research Article
Abstract: Background: Repetitive transcranial magnetic stimulation (rTMS) is a promising tool to study and modulate brain plasticity. Objective: Our aim was to investigate the effects of rTMS on cognitive functions in patients with mild cognitive impairment and Alzheimer’s disease (MCI/AD) and assess the effect of gray matter (GM) atrophy on stimulation outcomes. Methods: Twenty MCI/AD patients participated in the proof-of-concept controlled study. Each patient received three sessions of 10 Hz rTMS of the right inferior frontal gyrus (IFG), the right superior temporal gyrus (STG), and the vertex (VTX, a control stimulation site) in a …randomized order. Cognitive functions were tested prior to and immediately after each session. The GM volumetric data of patients were: 1) compared to healthy controls (HC) using source-based morphometry; 2) correlated with rTMS-induced cognitive improvement. Results: The effect of the stimulated site on the difference in cognitive scores was statistically significant for the Word part of the Stroop test (ST-W, p = 0.012, linear mixed models). As compared to the VTX stimulation, patients significantly improved after both IFG and STG stimulation in this cognitive measure. MCI/AD patients had significant GM atrophy in characteristic brain regions as compared to HC (p = 0.029, Bonferroni corrected). The amount of atrophy correlated with the change in ST-W scores after rTMS of the STG. Conclusion: rTMS enhanced cognitive functions in MCI/AD patients. We demonstrated for the first time that distinct pattern of GM atrophy in MCI/AD diminishes the cognitive effects induced by rTMS of the temporal neocortex. Show more
Keywords: Alzheimer’s disease, brain atrophy, cognitive functions, noninvasive brain stimulation; source-based morphometry
DOI: 10.3233/JAD-150067
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 251-260, 2015
Authors: Kelly, David | Coen, Robert F. | Akuffo, Kwadwo Owusu | Beatty, Stephen | Dennison, Jessica | Moran, Rachel | Stack, Jim | Howard, Alan N. | Mulcahy, Riona | Nolan, John M.
Article Type: Research Article
Abstract: Background: Macular pigment (MP) levels correlate with brain concentrations of lutein (L) and zeaxanthin (Z), and have also been shown to correlate with cognitive performance in the young and elderly. Objective: To investigate the relationship between MP, serum concentrations of L and Z, and cognitive function in subjects free of retinal disease with low MP (Group 1, n = 105) and in subjects with AMD (Group 2, n = 121). Methods: MP was measured using customized heterochromatic flicker photometry and dual-wavelength autofluorescence; cognitive function was assessed using a battery of validated cognition tests; serum L and Z …concentrations were determined by HPLC. Results: Significant correlations were evident between MP and various measures of cognitive function in both groups (r = –0.273 to 0.261, p ≤0.05, for all). Both serum L and Z concentrations correlated significantly (r = 0.187, p ≤0.05 and r = 0.197, p ≤0.05, respectively) with semantic (animal) fluency cognitive scores in Group 2 (the AMD study group), while serum L concentrations also correlated significantly with Verbal Recognition Memory learning slope scores in the AMD study group (r = 0.200, p = 0.031). Most of the correlations with MP, but not serum L or Z, remained significant after controlling for age, gender, diet, and education level. Conclusion: MP offers potential as a non-invasive clinical biomarker of cognitive health, and appears more successful in this role than serum concentrations of L or Z. Show more
Keywords: Age-related macular degeneration, biomarker, cognitive function, lutein, macular pigment, zeaxanthin
DOI: 10.3233/JAD-150199
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 261-277, 2015
Authors: Matsuzono, Kosuke | Hishikawa, Nozomi | Yamashita, Toru | Ohta, Yasuyuki | Sato, Kota | Kono, Shoichiro | Deguchi, Kentaro | Morihara, Ryuta | Abe, Koji
Article Type: Research Article
Abstract: Background/Objective: To examine comprehensive clinical evaluations of frontotemporal dementia (FTD) patients compared with Alzheimer’s disease (AD) patients. Methods: We used eight batteries and the touch panel test to retrospectively analyze 41 FTD patients compared with 121 AD patients. Furthermore, 34 FTD and all 121 AD patients were evaluated with a frontotemporal dementia-Alzheimer’s disease index (FA index), which we developed for novel diagnosis with magnetic resonance imaging. Results: Frontal assessment battery, geriatric depression scale, and Abe’s behavioral and psychological symptom of dementia score were significantly worse in FTD patients than in AD patients ( ** p … < 0.01 in FAB, ** p < 0.01 in the geriatric depression scale, and *** p < 0.001 in Abe’s behavioral and psychological symptom of dementia score), although there was no significant difference in the other five scores. The finding mistakes game score of the touch panel test was worse in FTD than in AD ( * p < 0.05). The receiver operating characteristic curve of the FA index showed 91.4% sensitivity and 89.3% specificity with the FA index ≤0.6015 to discriminate FTD from AD. Conclusion: Combining clinical scores, a computerized touch panel test, and the FA index will help to provide a more accurate diagnosis of FTD in contrast to AD. Show more
Keywords: Alzheimer’s disease, frontotemporal dementia, magnetic resonance imaging, touch panel test
DOI: 10.3233/JAD-150416
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 279-286, 2015
Article Type: Meeting Report
DOI: 10.3233/JAD-150550
Citation: Journal of Alzheimer's Disease, vol. 48, no. 1, pp. 287-291, 2015
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]